Triphasic oral contraceptive

Details Triphasic oral contraceptive Triphasic oral contraceptive

A - Human Necessities

61

K

167/193

A61K 31/56 (2006.01) A61K 31/565 (2006.01)

Patent

CA 1226221

TRIPHASIC ORAL CONTRACEPTIVE ABSTRACT A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-ethinylestra- diol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 6-8 days without administering either an estrogen or a progestogen.

462334

Affiliated with

Also associated with

Rating

Triphasic oral contraceptive does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triphasic oral contraceptive, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triphasic oral contraceptive will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1187942